Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis;Multiple-sklerose-update zur pathophysiologie und neuen immuntherapeutischen ansätzen

Nervenarzt

Volumn 78, Issue 8, 2007, Pages 883-911

  Kleinschnitz, C ^a   Meuth, S G ^a   Kieseier, B C ^b   Wiendl, H ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Immunomodulation; Immunosuppression; Multiple sclerosis; Neurodegeneration; Neuroprotection; Therapy

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; A 7711726; ABATACEPT; ABT 874; ALEMTUZUMAB; AZATHIOPRINE; BBR 2778; CDP 323; CNTO 1275; CYCLOPHOSPHAMIDE; DACLIZUMAB; DIZOCILPINE; EFALIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; IBUDILAST; IDC 131; IMMUNOGLOBULIN; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 4; LAQUINIMOD; MBP 8298; MESOPRAM; METHOTREXATE; MITOXANTRONE; MUROMAB; MYELIN; NATALIZUMAB; NEUROPROTECTIVE AGENT; OKT 4; PHOSPHODIESTERASE INHIBITOR; PIOGLITAZONE; PRILIXIMAB; RG 2077; RITUXIMAB; ROLIPRAM; ROQUINIMEX; ROSIGLITAZONE; SB 683699; TGN 1412; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; AXONAL INJURY; CD8+ T LYMPHOCYTE; CHEMOTAXIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PLASMAPHERESIS; REMYELINIZATION; REVIEW; TREATMENT OUTCOME;

AUTOANTIGENS; B-LYMPHOCYTES; BLOOD-BRAIN BARRIER; BRAIN; CELL DEATH; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINES; DENDRITIC CELLS; FREE RADICALS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICROGLIA; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROPROTECTIVE AGENTS; PROGNOSIS; RETROGRADE DEGENERATION; T-LYMPHOCYTES;

EID: 34547896687     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-007-2261-9     Document Type: Review

References (227)

1. Aboul-Enein F, Bauer J, Klein M et al. (2004) Selective and antigen-dependent effects of myelin degeneration on central nervous system inflammation. J Neuropathol Exp Neurol 63: 1284-1296
2. Abrams JR, Lebwohl MG, Guzzo CA et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103: 1243-1252
3. Acha-Orbea H, Mitchell DJ, Timmermann L et al. (1988) Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 54: 263-273
4. Achiron A, Lavie G, Kishner I et al. (2004) T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients. Clin Immunol 113: 155-160
5. Agnello D, Bigini P, Villa P et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952: 128-134
6. Ahrens N, Salama A, Haas J (2001) Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 248: 713-714
7. Alegre ML, Sattar HA, Herold KC et al. (1994) Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 57: 1786-1794
8. Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6: 205-217
9. Andersen O, Lycke J, Tollesson PO et al. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895-900
10. Antel JP, Bar-Or A (2003) Do myelin-directed antibodies predict multiple sclerosis? N Engl J Med 349: 107-109
11. Archelos JJ, Hartung HP (2000) Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci 23: 317-327
12. Arroyo AG, Yang JT, Rayburn H, Hynes RO (1996) Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 85: 997-1008
13. Babbe H, Roers A, Waisman A et al. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192: 393-404
14. Baecher-Allan C, Hafler DA (2004) Suppressor T cells in human diseases. J Exp Med 200: 273-276
15. Baker D, Pryce G, Croxford JL et al. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404: 84-87
16. Bar-Or A, Antel J, Bodner CA (2006) Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Neurology [Suppl 66]: A62-A62
17. Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55: 458-468
18. Bechtold DA, Kapoor R, Smith KJ (2004) Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55: 607-616
19. Beeton C, Wulff H, Barbaria J et al. (2001) Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 98: 13942-13947
20. Ben-Nun A, Cohen IR (1981) Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur J Immunol 11: 949-952
21. Benoist C, Mathis D (2001) Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2: 797-801
22. Berger T, Rubner P, Schautzer F et al. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349: 139-145
23. Bielekova B, Catalfamo M, Reichert-Scrivner S et al. (2006) Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103: 5941-5946
24. Bielekova B, Goodwin B, Richert N et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6: 1167-1175
25. Bielekova B, Lincoln A, McFarland H, Martin R (2000) Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 164: 1117-1124
26. Bielekova B, Richert N, Howard T et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 101: 8705-8708
27. Bisikirska B, Colgan J, Luban J et al. (2005) TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 115: 2904-2913
28. Bjartmar C, Trapp BD (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr Opin Neurol 14: 271-278
29. Black JA, Dib-Hajj S, Baker D et al. (2000) Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Natl Acad Sci U S A 97: 11598-11602
30. Blanco Y, Saiz A, Carreras E, Graus F (2005) Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. Lancet Neurol 4: 54-63
31. Bolton C, Paul C (1997) MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282: 397-402
32. Boneberg EM, Hartung T (2002) Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1beta release via suppressed processing of proIL-1beta, whereas TNF-alpha release is inhibited on the level of proTNF-alpha formation. Eur J Immunol 32: 1717-1725
33. Bothwell M (1995) Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 18: 223-253
34. Bourdette DN, Whitham RH, Chou YK et al. (1994) Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 152: 2510-2519
35. Bowen JD, Petersdorf SH, Richards TL et al. (1998) Phase I-Study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin Pharmacol Ther 64: 339-346
36. Brand-Schieber E, Werner P (2004) Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp Neurol 189: 5-9
37. Brinkmann V, Davis MD, Heise CE et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457
38. Brok HP, Meurs M van, Blezer E et al. (2002) Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol 169: 6554-6563
39. Brundula V, Rewcastle NB, Metz LM et al. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125: 1297-1308
40. Brunmark C, Runstrom A, Ohlsson L et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130: 163-172
41. Budde K, Schmouder RL, Brunkhorst R et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13: 1073-1083
42. Carreno BM, Collins M (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 20: 29-53
43. Cepok S, Zhou D, Srivastava R et al. (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 115: 1352-1360
44. Chang A, Tourtellotte WW, Rudick R, Trapp BD (2002) Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 346: 165-173
45. Charo IF, Ransohoff RM (2006) The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354: 610-621
46. Chen BJ, Morris RE, Chao NJ (2000) Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol Blood Marrow Transplant 6: 529-536
47. Chitnis T, Imitola J, Khoury SJ (2005) Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord 5: 11-26
48. Chunduru SK, Sutherland RM, Stewart GA et al. (1996) Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. J Immunol 156: 4940-4945
49. Ciric B, Howe CL, Paz Soldan M et al. (2003) Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 13: 608-616
50. Clements JM, Cossins JA, Wells GM et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74: 85-94
51. Cohen J (1995) IL-12 deaths: explanation and a puzzle. Science 270: 908
52. Coles AJ, Wing MG, Molyneux P et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46: 296-304
53. Columba-Cabezas S, Serafini B, Ambrosini E et al. (2002) Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol 130: 10-21
54. Craner MJ, Damarjian TG, Liu S et al. (2005) Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49: 220-229
55. Craner MJ, Lo AC, Black JA, Waxman SG (2003) Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 126: 1552-1561
56. Cyster JG (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23: 127-159
57. Dello Russo C, Gavrilyuk V, Weinberg G et al. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278: 5828-5836
58. Delorenze GN, Munger KL, Lennette ET et al. (2006) Epstein-Barr Virus and Multiple Sclerosis: Evidence of Association From a Prospective Study With Long-term Follow-up. Arch Neurol 63: 839-844
59. Diab A, Deng C, Smith JD et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 168: 2508-2515
60. Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404-410
61. Dyke HJ, Montana JG (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11: 1-13
62. Ehrenreich H, Aust C, Krampe H et al. (2004) Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 19: 195-206
63. Elices MJ (2002) BX-471 Berlex. Curr Opin Investig Drugs 3: 865-869
64. Engelhardt B, Briskin MJ (2005) Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur J Immunol 35: 2268-2273
65. Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26: 485-495
66. Farrell R, Heaney D, Giovannoni G (2005) Emerging therapies in multiple sclerosis. Expert Opin Emerg Drugs 10: 797-816
67. Fassas A, Passweg JR, Anagnostopoulos A et al. (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249: 1088-1097
68. Ferrante P, Fusi ML, Saresella M et al. (1998) Cytokine production and surface marker expression in acute and stable multiple sclerosis: altered IL-12 production and augmented signaling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 160: 1514-1521
69. Filippi M (2002) The role of magnetic resonance imaging in the assessment of patients with established multiple sclerosis. Neurol Sci 23: 89-90
70. Filippi M, Rovaris M, Rice GP et al. (2000) The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 176: 42-44
71. Fontoura P, Garren H, Steinman L (2005) Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol 24: 415-446
72. Fox RJ, Ransohoff RM (2004) New directions in MS therapeutics: vehicles of hope. Trends Immunol 25: 632-636
73. Frauwirth KA, Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109: 295-299
74. Friese MA, Montalban X, Willcox N et al. (2006) The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952
75. Frohman EM, Brannon K, Racke MK, Hawker K (2004) Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 27: 80-83
76. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 354: 942-955
77. Fujimoto T, Sakoda S, Fujimura H, Yanagihara T (1999) Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 95: 35-42
78. Fujino M, Funeshima N, Kitazawa Y et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305: 70-77
79. Gately MK, Renzetti LM, Magram J et al. (1998) The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521
80. Genc K, Genc S, Baskin H, Semin I (2006) Erythropoietin decreases cytotoxicity and nitric oxide formation induced by inflammatory stimuli in rat oligodendrocytes. Physiol Res 55: 33-38
81. Genc S, Koroglu TF, Genc K (2004) Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 22: 105-119
82. Germain RN, Stefanova I (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 17: 467-522
83. Giuliani F, Fu SA, Metz LM, Yong VW (2005) Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 165: 83-91
84. Gold R, Havrdova E, Kappos L et al. (2006) Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting mutiple sclerosis: results of a phase 2 study. J Neurol 253: 144
85. Gonsette RE, Dubois B (2004) Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J Neurol Sci 223: 81-86
86. Goodkin DE, Shulman M, Winkelhake J et al. (2000) A phase I trial of solubilized DR2: MBP84-102 (AG284) in multiple sclerosis. Neurology 54: 1414-1420
87. Gordon EJ, Myers KJ, Dougherty JP et al. (1995) Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 62: 153-160
88. Greter M, Heppner FL, Lemos MP et al. (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11: 328-334
89. Hickey WF, Kimura H (1988) Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239: 290-292
90. Hohlfeld R, Wekerle H (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A [Suppl 2] 101: 14599-14606
91. Hohlfeld R, Wiendl H (2001) The ups and downs of multiple sclerosis therapeutics. Ann Neurol 49: 281-284
92. Howard LM, Kohm AP, Castaneda CL, Miller SD (2005) Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr Drug Targets Inflamm Allergy 4: 205-216
93. Howell MD, Winters ST, Olee T et al. (1989) Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science 246: 668-670
94. Huitinga I, Ruuls SR, Jung S et al. (1995) Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol 100: 344-351
95. Jiang H, Kashleva H, Xu LX et al. (1998) T cell vaccination induces T cell receptor Vbeta-specific Qa-1-restricted regulatory CD8(+) T cells. Proc Natl Acad Sci U S A 95: 4533-4537
96. Jonsson S, Andersson G, Fex T et al. (2004) Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47: 2075-2088
97. Kalkers NF, Barkhof F, Bergers E et al. (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 8: 532-533
98. Kappos L, Antel J, Comi G et al. (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140
99. Kappos L, Barkhof F, Desmet A (2005) The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J Neurol [Suppl 42] 252: 46-46
100. Kappos L, Comi G, Panitch H et al. (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6: 1176-1182
101. Kappos L, Miller DH, MacManus DG et al. (2006) Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. J Neurol 253: 27
102. Kawai T, Andrews D, Colvin RB et al. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114
103. Keegan M, Konig F, McClelland R et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579-582
104. Keeley KA, Rivey MP, Allington DR (2005) Natalizumab for the treatment of multiple sclerosis and Crohn's disease. Ann Pharmacother 39: 1833-1843
105. Kerschensteiner M, Stadelmann C, Dechant G et al. (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53: 292-304
106. Killestein J, Olsson T, Wallstrom E et al. (2002) Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial. Ann Neurol 51: 467-474
107. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374
108. Kleinschnitz C, Schroeter M, Jander S, Stoll G (2004) Induction of granulocyte colony-stimulating factor mRNA by focal cerebral ischemia and cortical spreading depression. Brain Res Mol Brain Res 131: 73-78
109. Klotz L, Schmidt M, Giese T et al. (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175: 4948-4955
110. Kobata T, Azuma M, Yagita H, Okumura K (2000) Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2: 74-80
111. Kohm AP, Williams JS, Bickford AL et al. (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol 174: 4525-4534
112. Konno H, Yamamoto T, Iwasaki Y et al. (1989) Ia-expressing microglial cells in experimental allergic encephalomyelitis in rats. Acta Neuropathol (Berl) 77: 472-479
113. Korn T, Magnus T, Toyka K, Jung S (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion. J Leukoc Biol 76: 950-960
114. Kornek B, Storch MK, Bauer J et al. (2001) Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 124: 1114-1124
115. Krumbholz M, Theil D, Derfuss T et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195-200
116. Kwak B, Mulhaupt F, Myit S, Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402
117. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7: 115-121
118. Lebwohl M, Tyring SK, Hamilton TK et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004-2013
119. Lennon VA, Kryzer TJ, Pittock SJ et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477
120. Li W, Maeda Y, Yuan RR et al. (2004) Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann Neurol 56: 767-777
121. Lim ET, Berger T, Reindl M et al. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 11: 492-494
122. Lindsey JW, Hodgkinson S, Mehta R et al. (1994) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 36: 183-189
123. Linsley PS, Brady W, Urnes M et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174: 561-569
124. Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90: 3566-3571
125. Lovett-Racke AE, Bittner P, Cross AH et al. (1998) Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 101: 1797-1804
126. Lublin F (1999) A phase II trial of anti-CD11/CD18 monoclonal antibody in acute exacerbations of MS. Neurology 52 [Suppl 2]
127. Lucchinetti C, Bruck W, Parisi J et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717
128. Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55: 300-309
129. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F (2004) Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 11-23
130. Magnus T, Schreiner B, Korn T et al. (2005) Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci 25: 2537-2546
131. Mancardi GL, Saccardi R, Filippi M et al. (2001) Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 57: 62-68
132. Mandala S, Hajdu R, Bergstrom J et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349
133. Marecki S, Kirkpatrick P (2004) Efalizumab. Nat Rev Drug Discov 3: 473-474
134. Marracci GH, McKeon GP, Marquardt WE et al. (2004) Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res 78: 362-370
135. Matloubian M, Lo CG, Cinamon G et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360
136. McDonald WI, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127
137. Meden H, Mielke S, Marx D et al. (1997) Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res 17: 3075-3077
138. Meinl E, Weber F, Drexler K et al. (1993) Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 92: 2633-2643
139. Metz LM, Zhang Y, Yeung M et al. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 55: 756
140. Miller DH, Khan OA, Sheremata WA et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348: 15-23
141. Monson NL, Cravens PD, Frohman EM et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62: 258-264
142. Morini M, Roccatagliata L, Dell'Eva R et al. (2004) Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 148: 146-153
143. Muller H, Hofer S, Kaneider N et al. (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35: 533-545
144. Muraro PA, Douek DC, Packer A et al. (2005) Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 201: 805-816
145. Nash RA, Bowen JD, McSweeney PA et al. (2003) High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 102: 2364-2372
146. Nashmi R, Fehlings MG (2001) Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev 38: 165-191
147. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59: 990-997
148. Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25: 313-319
149. Niino M, Bodner C, Simard ML et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748-754
150. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343: 938-952
151. Noseworthy JH, Wolinsky JS, Lublin FD et al. (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators [see comments]. Neurology 54: 1726-1733
152. O'Connor PW, Li D, Freedman MS (2006) A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900
153. Paemen L, Martens E, Norga K et al. (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 52: 105-111
154. Paolillo A, Coles AJ, Molyneux PD et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53: 751-757
155. Pershadsingh HA (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13: 215-228
156. Pershadsingh HA, Heneka MT, Saini R et al. (2004) Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation 1: 3
157. Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70
158. Platten M, Steinman L (2005) Multiple sclerosis: trapped in deadly glue. Nat Med 11: 252-253
159. Polman C, Barkhof F, Sandberg-Wollheim M et al. (2005) Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64: 987-991
160. Polman CH, O'Connor PW, Havrdova E et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910
161. Pryce G, Ahmed Z, Hankey DJ et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126: 2191-2202
162. Putheti P, Pettersson A, Soderstrom M et al. (2004) Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J Clin Immunol 24: 155-161
163. Qin Y, Duquette P, Zhang Y et al. (2003) Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest 83: 1081-1088
164. Ransohoff RM (2005) Natalizumab and PML. Nat Neurosci 8: 1275
165. Rice GP, Filippi M, Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI-Study Group. Neurology 54: 1145-1155
166. Rizvi SA, Bashir K (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 12 [Suppl 6] (63): 47-54
167. Rumbach L, Racadot E, Armspach JP et al. (1996) Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Mult Scler 1: 207-212
168. Rutella S, Zavala F, Danese S et al. (2005) Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 175: 7085-7091
169. Saccardi R, Mancardi GL, Solari A et al. (2005) Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 105: 2601-2607
170. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352
171. Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19: 225-252
172. Samijn JP, Boekhorst PA te, Mondria T et al. (2006) Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 77: 46-50
173. Saruhan-Direskeneli G, Weber F, Meinl E et al. (1993) Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone. Eur J Immunol 23: 530-536
174. Scheinfeld N (2006) Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5: 197-209
175. Schimrigk S, Brune N, Hellwig K et al. (2006) Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13: 604-610
176. Schneider-Gold C, Hartung HP, Gold R (2006) Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases. Muscle Nerve 34: 284-291
177. Scott GS, Spitsin SV, Kean RB et al. (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99: 16303-16308
178. Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35: 7S-14S
179. Sellebjerg F, Sorensen TL (2003) Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res Bull 61: 347-355
180. Sicotte NL, Giesser BS, Tandon V (2006) A pilot study of testosterone treatment for men with relapsing remitting multiple sclerosis. Neurology 66: A30
181. Sicotte NL, Liva SM, Klutch R et al. (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52: 421-428
182. Sidiropoulos PI, Boumpas DT (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13: 391-397
183. Simmons DL, Buckley CD (2005) Some new, and not so new, anti-inflammatory targets. Curr Opin Pharmacol 5: 394-397
184. Sipe JC (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5: 721-727
185. Sipe JC, Romine JS, Koziol J et al. (1997) Cladribine improves relapsing-remitting MS: a double blind placebo controlled study. Neurology 48: A340
186. Sipe JC, Romine JS, Koziol JA et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis [see comments]. Lancet 344: 9-13
187. Sjoo F, Hassan Z, Abedi-Valugerdi M et al. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp Hematol 34: 115-121
188. Smilek DE, Wraith DC, Hodgkinson S et al. (1991) A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 88: 9633-9637
189. Sospedra M, Martin R (2005) Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 24: 393-413
190. Steinman L (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4: 510-518
191. Steinman L (2001) Multiple sclerosis: a two-stage disease. Nat Immunol 2: 762-764.
192. Storer PD, Xu J, Chavis J, Drew PD (2005) Peroxisome proliferator- activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol 161: 113-122
193. Stuve O, Youssef S, Weber MS et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116: 1037-1044
194. Suntharalingam G, Perry MR, Ward S et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028
195. Thoenen H, Sendtner M (2002) Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 5 [Suppl]: 1046-1050
196. Trebst C, Stangel M (2006) Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Curr Pharm Des 12: 241-249
197. Tubridy N, Behan PO, Capildeo R et al. (1999) The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS. Neurology 53: 466-472
198. Utset TO, Auger JA, Peace D et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29: 1907-1913
199. Van Assche G, Van Ranst M, Sciot R et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362-368
200. Van der Aa A, Hellings N, Medaer R et al. (2003) T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study. Clin Exp Immunol 131: 155-168
201. Oosten BW van, Barkhof F, Truyen L et al. (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534
202. Oosten BW van, Lai M, Barkhof F et al. (1996) A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Mult Scler 1: 339-342
203. Vandenbark AA, Chou YK, Whitham R et al. (1996) Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Medicine 2: 1109-1115
204. Vennekamp J, Wulff H, Beeton C et al. (2004) Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65: 1364-1374
205. Vermersch P, Waucquier N, Bourteel H (2004) Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and Mycophenolate mofetil (Cellcept): Results of a phase II clinical trial. Neurology 62: A259
206. Vianna-Jorge R, Suarez-Kurtz G (2004) Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders? BioDrugs 18: 329-341
207. Villoslada P, Hauser SL, Bartke I et al. (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191: 1799-1806
208. Vincenti F, Kirkman R, Light S et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 338: 161-165
209. Vollmer T, Key L, Durkalski V et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607-1608
210. Waldmann H (1989) Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 7: 407-444
211. Warren KG, Catz I, Wucherpfennig KW (1997) Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci 152: 31-38
212. Waxman SG, Craner MJ, Black JA (2004) Na+ channel expression along axons in multiple sclerosis and its models. Trends Pharmacol Sci 25: 584-591
213. Weiner HL, Mackin GA, Matsui M et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259: 1321-1324
214. Weinshenker BG, Bass B, Karlik S et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41: 1047-1052
215. Weissert R, Wiendl H, Pfrommer H et al. (2003) Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J Neuroimmunol 144: 28-37
216. Werner P, Pitt D, Raine CS (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50: 169-180
217. Wiendl H, Hohlfeld R (2002) Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16: 183-200
218. Wiendl H, Kieseier BC, Weissert R et al. (2007) Treatment of active secondary progressive multiple sclerosis with treosulfan: an open label pilot study. J Neurol (in press)
219. Willenborg DO, Staykova MA, Miyasaka M (1996) Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol 157: 1973-1980
220. Yadav V, Marracci G, Lovera J et al. (2005) Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 11: 159-165
221. Yong VW, Wells J, Giuliani F et al. (2004) The promise of minocycline in neurology. Lancet Neurol 3: 744-751
222. Yousry TA, Major EO, Ryschkewitsch C et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933
223. Youssef S, Stuve O, Patarroyo JC et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84
224. Zajicek J, Fox P, Sanders H et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517-1526
225. Zang YC, Hong J, Rivera VM et al. (2000) Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 164: 4011-4017
226. Zipp F, Hartung HP, Hillert J et al. (2005) Blockade of chemokine receptor in multiple sclerosis patients. Mult Scler 11: S13
227. Zipp F, Krammer PH, Weller M (1999) Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol Today 20: 550-554